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A cluster of pneumonia cases of unknown origin was detected on December 31th which 
led to the discovery of coronavirus disease 2019 (COVID-19). Lungs are the primary 
site of involvement. SARS-COV-2, which is the causative agent, enters the alveolar 
cells using ACE2 as a receptor. Due to exposure of first cases to Wuhan’s animal 
market, a zoonotic transmission was suspected. Further studies suggested human to 
human transmission through contact and droplets. Symptoms vary from asymptomatic 
to acute respiratory distress syndrome and death. Cases are diagnosed based on clin-
ical and laboratory findings. Currently, there is no definitive treatment or vaccine and 
different antiviral and other treatments are being tested as possible therapeutic agents 
with different mechanisms, for example, Chloroquine, hydroxychloroquine, azithromy-
cin, favipiravir, umifenovir, ribavirin, Ivermectin, etc.
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INTRODUCTION
On December 31th, 2019, a group of pneumonia cases of un-
known origin in the city of Wuhan in the Hubei Province in 
China was detected [1] which was later found out to be caused 
by a new emerging β-coronavirus, called 2019 novel coronavi-
rus (2019-nCoV) or Severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2) [2]. On February 8th, 2020 pneumonia 
caused by this agent was afterward named Novel Coronavirus 
Pneumonia (NCP) [3] which was later changed to Coronavi-
rus infection disease 2019 (COVID-19). COVID-19 starting in 
China, rapidly spread to other parts of the country and other 
nations [4] as well, with an exponential growth rate [5] so as 
until May 6th, 2020 causing 3,557,235 confirmed cases and 
245,150 deaths worldwide with the United States, Spain and 
Italy being affected the most [6]. On January 30th, 2020 the 
world health organization declared a state of Public health 
emergency of international concern (PHEIC) for the sixth time 
[5], and on March 11th, 2020 WHO assessed COVID-19 as 
a pandemic [7]. SARS-CoV-2 is an enveloped, single-strand-
ed, positive-sense, zoonotic member of β-coronaviruses [4, 8]
which are known for causing more severe and lethal disease 
[4] as in previous major epidemics like severe acute respirato-
ry syndrome (SARS) and middle-eastern respiratory syndrome 
(MERS) [2]. The first cases had a history of being in touch with 
seafood or animal wholesale markets which raised the suspi-
cion of zoonotic transmission [9, 10], and bats were assumed 
to be the reservoir host [11]. The virus has an incubation period 
of 1 to 14 days, which for most cases, an incubation period of 4 
days has been reported [3, 5, 11] and can be transmitted through 
droplets, contaminated objects, and Human-to-Human contact 
whether being symptomatic or asymptomatic. COVID-19 con-
firmed cases are seen mostly among adults with children under 
10 only accounting for 0.9% cases [12] and mostly being as-
ymptomatic or having mild forms of the disease so having the 
capacity to act as carriers [1, 4]. Patients mostly complain of 
fever, dry cough, and myalgia with associated laboratory and 
radiological findings. There is no specific treatment or vaccine 
for COVID-19 until now but several potential options under 
investigation. In this study we aim to have a look into potential 
pharmacologic treatment options for COVID-19.
MATERIALS and METHODS
On March 11th, 2020 search engines such as Pubmed, Scopus, 
Clinicalkey, Cochrane library and Embase were used to search 
‘SARS2 and treatment’, ’SARS2 and therapy’, ’COVID 19 and 
therapy’,’covid19 and treatment’ and ‘COVID 19 and drug’ re-
Article Info
Date Submitted: 6 May, 2020
Available Online: 25 May, 2020
Keywords
SARS-CoV-2, COVID-19, ARDS, phar-
macology, treatment, therapeutic options
2 • School of Medicine Students‘ Journal (2020) 2:2
have also been suspected [10]. There is no evidence suggesting 
vertical mother to child transmission [16].
Clinical manifestation
COVID-19 is an acute respiratory disease. It is present in mild, 
moderate, and severe forms which, affects all groups of people 
but it is mostly seen in adults [10]. Children usually are asymp-
tomatic or manifest mild gastrointestinal symptoms [3, 12]. 
Adults are symptomatic featuring 3 common symptoms of fe-
ver, dry cough, and myalgia. Other symptoms including chills, 
shortness of breath, chest pain, malaise, fatigue, headache, na-
sal congestion, rhinorrhea  [3, 10, 17] and GI symptoms such as 
nausea, abdominal pain and diarrhea [18] and dyspnea which is 
a sign of disease progression [4], has been reported within less 
than a week. During the second and third weeks of symptom-
atic infection, signs of pneumonia have been discovered within 
75% of patients. On physical examination patients based on 
the severity of the disease have various findings, ranging from 
normal findings to respiratory distress, tachycardia, and fever. 
There has been no specific diagnostic laboratory findings but 
among the tests, elevated levels of Aspartate aminotransfer-
ase (AST), Alanine aminotransferase (ALT), lactate dehydro-
genase (LDH), C-reactive protein (CRP), and lactate [19, 20] 
have been found alongside a leukopenia consisting of neutro-
penia and lymphopenia which is a criteria of poor prognosis 
[10, 15]. Imaging studies with computed tomography (CT) has 
been used as a complementary diagnostic tool as well and find-
ings are usually seen, 10 days after onset of the symptoms [21]. 
These studies revealed a range of findings from no findings in 
a few cases to unilateral and bilateral pulmonary engagement 
[22]. Increased bilateral para hilar infiltration and ill-defined 
irregular patchy consolidations with increased thickening of re-
ticular or interlobular septa were seen [3, 23]. Bilateral periph-
eral Grand glass opacities [24] may also be seen in CT images 
[25]. In some cases some uncommon findings such as small 
bilateral pleural effusions and mediastinal lymphadenopathy 
was also detected [21].
Diagnosis
Clinical manifestation such as cough, fever and myalgia are be-
ing used as a primitive screening tool determining the necessity 
of referral to medical centers. A definitive diagnosis is estab-
lished based on laboratory reports. Sputum, nasopharyngeal 
swabs, oropharyngeal swabs, blood, urine and feces [10, 17] 
were used as samples for diagnosis and treatment procedure 
follow up. Currently there is no definitive serologic diagnos-
tic laboratory finding. Diagnosis is established based on the 
presence of viral genome. Real-time reverse transcription poly-
merase chain reaction (rRT-PCR) is mostly used for this cause 
along with RNA-based metagenomic sequencing and CRIS-
PR-based technique [1, 5, 26]. Besides IgM/IgG anti-SARS-
CoV-2 antibodies can also be used as a means of diagnosis 
[27]. Imaging studies are also a promising diagnostic tool.
Pharmacologic management
Various treatments are assorted based on different stages of 
coronavirus entrance, virus replication, body reactions to the 
virus, and the effects of the Immune system on the virus.
sulting in a total of 68 articles which 29 articles were excluded 
due to repetition, irrelevancy, accessibility and language and 24 
articles were selected based on a revision of abstracts from the 
39 remaining articles. As follow up, another search was con-
ducted on March 22nd 2020 on Pubmed search engine with the 
“COVID-19 and treatment” keyword, from which 43 articles 
were selected by titles among 347 results and 40 were chosen 
further by abstracts.
Finally, on April 5th 2020, the LitCovid engine was searched 
under the treatment tab from April 1st until April 5th and 
among 139 of a total of 614 results,17 articles were selected 
by title which was further narrowed down to 14 due to rep-
etition and irrelevancy based on abstracts. Kowsarpub was 
also searched for COVID-19 and 14 articles were selected by 
title in the first step, among which 9 articles remained after 
further evaluation of abstracts. Pubmed was also searched for 
“COVID-19 AND favipiravir”,” COVID-19 AND umifeno-
vir”, “COVID-19 AND azithromycin” and “COVID-19 AND 
plasma therapy” that resulted in 3,4,3 and 7 articles respective-
ly. Later on, “covid-19 AND umifenovir” and “covid-19 AND 
azithromycin” were narrowed down to 3 and 2 results respec-
tively due to repetition and a lack of compatibility. At last, new 
drug choices based on computational studies were obtained 
and articles’ references were evaluated as well.
RESULTS and DISCUSSION
Pathogenesis
The main cells which are affected by COVID-19 seem to be 
alveolar type 2 cells which contain Angiotensin Converting 
Enzyme 2 (ACE 2) [9, 13]. Being a member of β-coronavirus-
es, SARS-CoV-2 has the crown figure on electron microscopic 
investigation. The spike (S) proteins, the spikes of the crown, 
bind to ACE2 and facilitates viral attachment through cellular 
surface into target cells [2]. From proteins among members of 
this family, ACE and ACE2 are of value. Angiotensin II, binds 
to AT1R on alveolar cells and activates it. ACE converts angio-
tensin I (produced by enzymatic actions of renin on angioten-
sinogen) into angiotensin II, a vasoconstrictor agent. ACE2 on 
the other hand opposes ACE’s function by inactivating angio-
tensin II and converting it to angiotensin 1-7, a heptapeptide 
with vasodilator functions. SARS-CoV-2 uses ACE2, as the 
receptor binding domain [13]. Alveolar damage caused by the 
virus leads to an increase in proinflammatory cytokines [14]
causing an interstitial inflammatory infiltration dominated by 
lymphocytes which contributes to more infiltration ultimate-
ly resulting in pneumocytes desquamation and hyaline mem-
brane formation indicating acute respiratory distress syndrome 
(ARDS) [15].
Transmission
The first detected cases of coronavirus had a history of con-
tact with bats which caused the suspicion of zoonotic measures 
[11]. Further studies suggested the presence of viruses in body 
fluids thus droplets and body fluids including sputum and blood 
could be a means of transmission so precautions should be 
taken towards blood donation [1, 5]. Direct human-to-human 
transmission and airborne transmission in small closed-areas 
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1- Inhibition of the coronavirus entrance into the body and 
binding to the receptor:
SARS-CoV-2 binds to the ACE2 and dysregulates the re-
nin-angiotensin system [13]. SARS-CoV-2 attaches to its re-
ceptor using its surface spike (S) protein [8]. Fusion and en-
trance are based on the binding of the S protein to the ACE2 
receptor on the cells. Due to the ACE2 role as a viral receptor, 
there are some suggestions to use AT1R antagonists (ARB) in 
COVID-19 treatment [5]. Experiments have proved that bind-
ing the coronavirus to its receptors on the cardiac cells, de-
creased ACE2 enzyme expression. This action results in ACE 
enzyme activation and produces angiotensin II. Considering 
these findings, taking AT1R antagonists seems to be a suitable 
option. Although  AT1R antagonists have rarely shown ad-
verse drug reactions, but hypotension is reporting in some of 
the SARS-CoV patients [13]. Both angiotensin converting en-
zyme inhibitors (ACEIs) and angiotensin II receptor blockers 
(ARBs) drugs have the same therapeutic effects and adverse 
effects; for example: Severe hypotension after initial doses, 
acute renal failure [28, 29]. Chloroquine was mentioned to in-
terfere with coronavirus-ACE2 interaction. Recombinant hu-
man monoclonal antibodies (mAb) could be used to interfere 
with virus binding according to Zhang et al. The mAb could ef-
ficiently neutralize SARS-CoV and inhibit syncytia formation 
between cells expressing the S protein and those expressing the 
SARS-CoV receptor ACE2 [8]. Peptide-based vaccines against 
coronavirus can not be utilized in subsequent epidemics con-
sidering mutations in the virus genome [13].
2- Inhibition of the coronavirus uncoating:
Chloroquine has shown in-vitro effects such as inhibition of 
uncoating and glycosylation in various viruses, so it is an ap-
propriate case study for COVID-19 treatment according to 
accomplished clinical trials conducted in China [5]. In chlo-
roquine administration, caution must be taken since profound 
side effects such as retinopathy may proceed. Chloroquine 
co-administration with lopinavir/ritonavir causes prolonged 
QT interval, torsades de pointes, and may result in sudden 
death [30]. Pruritus is common. Rare adverse effects include 
hemolysis in glucose- 6-phosphate dehydrogenase (G6PD)-de-
ficient persons, agranulocytosis, hypotension, and electrocar-
diographic changes [28].
3- Inhibition of viral replication:
Hydroxychloroquine inhibits virus replication in different 
steps: inhibition of the fusion of the virus to its receptor, in-
hibition of the nucleic acid replication, virus assembly, and 
virus release (32). In a study, the therapeutic plan was using 
hydroxychloroquine for 5 days; the results supported the ap-
plication for SARS-CoV-2 infection treatment [31]. Another 
study which used hydroxychloroquine for 3 to 6 days, showed 
that it could decrease viral load reduction in COVID-19 pa-
tients. Also, a combination of hydroxychloroquine and azithro-
mycin had synergic effects on viral elimination [32, 33]. Other 
antiviral treatments are as follows:
a) Ribavirin and interferon-β,  are virus replication inhibitors 
in animals and human cell lines. Adverse effects of ribavirin 
include hemolytic anemia and decreased hemoglobin. It is con-
traindicated in pregnant patients. 
b) Lopinavir/ritonavir (Kaletra): Lopinavir/ritonavir (LPV/
RTV) is a combination of lopinavir and ritonavir [34]. RTV 
inhibits the CYP3A-mediated metabolism of LPV, thereby in-
creasing the serum concentration of LPV[35]. This combination 
reduces coronavirus viral loads remarkably[36]. LPV inhibits 
polyprotein processing in CoV[34]. SARS-CoV2 and SARS-
CoV share a 79.5% sequence identity. LPV is useful for treating 
SARS and MERS patients, so it may be useful in COVID-19 
patients, too.  Chu et al have found out that the use of LPV/ RTV 
with ribavirin showed better results in the treatment of SARS 
[34]. Deng et al found that 16 patients who received arbidol and 
LPV/RTV had better clinical manifestation than LPV/RTV only 
[35]. Caution should be taken when taking Kaletra, since it can 
result in upper respiratory tract infection, vasodilation, throm-
bocytopenia, neutropenia, stevens-Johnson syndrome, transam-
inase increase, and a possible increase in myocardial infarction 
[28, 37]. 
c) Remdesivir: Remdesivir is an adenosine triphosphate ana-
logue and a broad-spectrum antiviral which affects viral RNA 
polymerase and terminates RNA transcription. [38-40]. It was 
primarily developed for Ebola treatment and demonstrated effec-
tiveness against SARS and MERS in animal models. A combina-
tion of remdesivir (RDV) and interferon-β have shown stronger 
antiviral activity against MERS-CoV to that of Lopinavir/ritona-
vir and IFN-β. Also, remdesivir unlike LPV/RTV-IFN-β, could 
reduce lung viral loads against MERS in animal study [8, 41]. 
It is currently under several clinical trials for assessing its effi-
cacy against COVID-19. Toxicity and adverse effects are under 
investigation.
d) Oseltamivir: The strategy that has been tried so far showed 
that 75 patients were administrated 75 mg oseltamivir, 500 mg 
ritonavir, 500 mg lopinavir, and the intravenous administration 
of 0.25 g ganciclovir for 3–14 days twice a day [11]. In a case 
series in Wuhan, China, most of the patients have been treat-
ed by oseltamivir, moxifloxacin, ceftriaxone, and azithromycin. 
Some of them received glucocorticoid therapy. Discharge rate of 
34.1% and the mortality rate of 4.3% have been observed [17]. 
The benefits of Oseltamivir on the course of treatment was un-
known [42].
e) Favipiravir is a broad-spectrum antiviral drug that inhibits 
viral replication. Favipiravir treatment increased the survival 
rate and decreased viral load. Favipiravir has potential drug-
drug interactions and in patients with basic diseases have to pay 
attention [43]. Favipiravir is contraindicated in pregnancy [44].
f) Protease inhibitors
Cinanserin, a known serotonin antagonist, which also showed 
hopeful SARS-CoV inhibitory features, is another possible op-
tion to be considered. It could inhibit the 3 chymotrypsin-like 
protease and could inhibit SARS-CoV replication [45]. The 
3C-L protease is encoded in SARS-CoV2. Therefore, Cinanse-
rin may be an effective therapy for the COVID-19 infection. 
Also, flavonoids like: Herbacetin, rhoifolin, and pectolinarin are 
3C-like protease inhibitors [8]. 
Nelfinavir is an HIV-1 protease inhibitor previously used in HIV 
treatment that acts through inhibition of 3C-L protein [45].
Carfilzomib is an approved anti-cancer drug which by inhibition 
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Glycyrrhizin, a component of licorice roots, is a traditional 
Chinese herbal medicine. Glycyrrhizin has inhibitory effects 
on SARS replication.
Baicalin, another Chinese herb was also found to be a SARS-
CoV inhibiting and immune system enhancer.
Shikonin is also another herbal medicine showing promising 
results [45].
Estradiol and phytoestrogen: Epidemiologic studies reveal men 
undergo a higher rate of morbidity and mortality in comparison 
to females after SARS-CoV infection. However an increase 
was reported in the number of female mice mortality after ova-
riectomy or administration of estrogen receptor antagonist [8].
i) Miscellaneous agents
Bictegravir an integrase inhibitor is a recently approved drug 
for HIV which can cause gastrointestinal, headache, and he-
patic side effects with dofetilide and rifampin contraindication 
[45, 58, 59].
Arbidol (Umifenovir): Arbidol prevents virus entrance into the 
cells through inhibition of the interaction between virus and 
plasma membrane [60]. Arbidol also can induce interferons 
and activate macrophages and be an immune enhancer [61]. 
Some patients received arbidol treatment at a dose of 0.4 g 
three times a day. Arbidol treatment improved the discharging 
rate and decreased the mortality rate [62]. 
Prulifloxacin is a fluoroquinolone with CYP1A2 inhibitory 
property which also showed anti-SARS-CoV-2 potential based 
on computational studies [63, 64].
Disulfiram an aldehyde dehydrogenase inhibitory agent, used 
in the treatment of alcoholism shows promise in inhibiting 
SARS-COV-2. Disulfiram has little side effects but causes 
drug-drug interactions with multiple drugs including phenyto-
in, isoniazid, oral anticoagulants. Alcohol consumption in a pa-
tient of disulfiram medication can lead to vomiting, sweating, 
throbbing headache, hypotension, and confusion. Its safety is 
not established in pregnancy [45, 65].
Carmofur is a known anti-neoplastic agent used in colorectal 
and breast cancers. It is known to cause leukoencephalopathy 
[45].
Tideglusib a glycogen synthase kinase 3 inhibitor with anti in-
flammatory features that was primarily developed for Alzhei-
mer’s disease [45, 66].
1-methylpropyl 2-imidazolyl disulfide (PX-12) is an inhibitor 
of thioredoxin-1 (Trx-1) which is associated with colorectal, 
gastric, and lung cancer [45, 67].
TDZD-8 is a thiadiazolidine derivative that has potential inhib-
itory effects on viral M protein. [45, 68]
Ivermectin is an anti-protozoal drug that has been in use since 
1970, is another option to be considered. According to studies, 
it has shown promising potential in laboratory studies and also 
had exhibited potential infection control in similar infections 
such as West Nile virus [69].
Moexipril, a long-acting ACE inhibitor prodrug; Daunorubi-
cin and Mitoxantrone, anthracycline antibiotics which are most 
widely used chemotherapy drugs [65]; Bepotastine, a non-se-
of proteasome shows potential for inhibiting COVID-19 pro-
tease [46].
Indinavir: It is an anti-HIV drug that based on molecular stud-
ies can also be used against SARS-COV-2 by potentially inhib-
iting the viral protease. Adverse effects are mostly of gastroin-
testinal and hepatic symptoms [47, 48].
Danoprevir: It is another HCV NS3/4 protease inhibitor has 
also shown potential according to the studies. It is also being 
used for Hepatitis C treatment.  Studies reveal a pharmacoki-
netic boost in co-administration of danoprevir with ritonavir 
[49].
Ledipasvir and velpatasvir, NS5A protein inhibitors of HCV 
have been proposed for further investigation due to virtual 
screening studies. Ledipasvir and velpatasvir in combination 
with sofosbuvir have been used as a potent anti-hepatitis C 
treatment. They may also cause headache, fatigue, and nausea 
as adverse effects [50].
SARS-CoV-2 M protein is the main enzyme utilized by the vi-
rus for replication, thus making it an appealing target. Studies 
suggest multiple agents that may or may not be approved by the 
FDA. For example: Telaprevir and boceprevir. These are α-ke-
toamide drugs that target the main protease of coronaviruses 
and 3C protease of enteroviruses and have a crucial role in the 
treatment of hepatitis C [51].
g) Immunoenhancers
Thymosin α-1 could control the spread of SARS disease. Meth-
ylprednisolone, a Corticosteroid agent, was often used during 
the acute respiratory distress syndrome (ARDS) and it De-
stroyed thymocytes. So, it is better to use thymosin α1 at the 
early illness, before ARDS happens [52].
Levamisole: This drug has different effects on the immune sys-
tem based on the dosing and the time of administration; immu-
nostimulant agent or immunosuppressive agent. A combination 
of levamisole and ascorbic acid was reported to be a lympho-
cyte enhancer [53].
h) Vitamins and supplements
B vitamins:  These Vitamins have a role in the immune sys-
tem and B vitamin deficiency could result in a weak immune 
system. So resolving B vitamin deficiencies is important for 
strengthening the body against the coronavirus [8]. 
Vitamin C: Vitamin C is necessary for immune system func-
tions [54]. Lower respiratory tract infection could be a result of 
COVID-19 disease, so vitamin C could be an effective option 
for the treatment of this infection [8]. 
Vitamin D3: Patients with a weak immune system as a re-
sult of vitamin D3 deficiency, are at a higher risk to infect to 
COVID-19 [55].
omega-3 Polyunsaturated fatty acids (PUFA)-derived lipid me-
diator:  This lipid mediator inhibited influenza virus replication 
strongly [8].
Selenium: Selenium deficiency affects the immune system re-
sponse and the virus elimination [56]. 
Ebselen: It’ an antioxidant agent with anti inflammatory and 
cytoprotective properties [45, 57].
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dating histamine 1 receptor antagonist [70]; rosuvastatin, an 
HMG-CoA reductase inhibitor which in some cases can cause 
hepatic toxicity and Atovaquone, [65] the antimalarial drug 
that is also used in pneumonia P. jiroveci [71] are also thera-
peutic options to be nominated for further investigations based 
on recent studies. 
4- Treatment of complications mediated by virus replica-
tion:
As the cytokine storm develops through the body, it caus-
es shock and hypoxemia. Also, Antimicrobial and antifungal 
agents could be administered for elongated illness course. Ap-
plication of prebiotics and Resolving nutritional deficiencies 
could be used alongside the main therapeutics. ARDS and dif-
ficulty in breathing are COVID-19 symptoms in which nitric 
oxide could help in regulating the function of the airways and 
inhibiting the synthesis of viral protein and RNA [8]. An effec-
tive way is to administer a combination, including anti-shock, 
antivirus, anti-secondary infection, anti-hypoxemia, and main-
tenance of water, electrolyte and acid-base balance, and micro 
ecological balance and immune enhancement. It could effec-
tively reduce the mortality rate in COVID-19 patients. [72].
Azithromycin, a macrolide and an erythromycin derivative, 
with unique pharmacologic properties and prolonged half-life, 
has been a part of the treatment options for community-ac-
quired pneumonia. It can be used alone or in combination 
with other antimicrobial agents, depending on the history and 
severity of the disease[29]. However, like other macrolides, 
through affecting potassium ion channels, prolongation of QT 
interval may happen and recent studies revealed an association 
of increased risk of cardiac death [28]. Taking azithromycin 
may cause increased lactate dehydrogenase, thrombocythemia, 
lymphocytopenia [37]. In a retrospective study of 85 fatal cas-
es, most patients received antibiotics (Meropenem), antiviral 
(Arbidol), and glucocorticoid treatments. The administration 
of multiple antibiotics did not decrease the mortality rate. This 
article did not mention azithromycin[73]. 
5- Managing Cytokine Release Syndrome Associated to 
coronavirus:
Regarding the importance of immune system functions against 
coronavirus, the WHO and CDC don’t recommend using corti-
costeroids routinely in early COVID-19 illness treatment plan 
unless there are other indications for their usage [42]. Whilst, 
the use of immunosuppressants (e.g. tocilizumab) is not ideal 
either, as it can suppress the immune system and lead to an 
increased risk of infection [31]. In severely ill patients the 
treatment of cytokine storm has become an important part of 
therapy. Tocilizumab is a blocker of the IL-6 receptor, which 
is a key molecule in cytokine release syndrome [74]. Taking 
tocilizumab may cause hypertension, peripheral edema, leuko-
penia, thrombocytopenia, and upper respiratory tract infection 
in some patients [37]. 
Convalescent Plasma Therapy is another way of managing the 
cytokine storm. Therapeutic Plasma Exchange (TPE) is not a 
novel approach as in 2014 it has been used against the Ebola 
virus. TPE has been kept as the last resort and previous studies 
confirmed a reduced mortality rate and hospital stay in patients 
receiving this treatment during SARS and MERS epidemics [75, 
76]. Convalescent plasma acquired from patients with severe 
disease might have higher titers of antibodies due to more in-
tense immune system response and so can last longer periods 
[76]. This medication seems to act through the suppression of 
viremia and managing the cytokine storm [27, 77]. TPE also 
seems to reset the hypercoagulable state and stabilize the endo-
thelial membranes [77]. Since viremia peaks in the first week of 
most viral illnesses, it has been suggested that early administra-
tion of TPE, can fill the gap between the entrance of the virus 
and primary immune response and can be more effective in the 
first weak rather than later [75]. No serious adverse drug reaction 
has been reported [75, 76]. However, as TPE is co-administrat-
ed with other therapeutic regimens, the antibody levels and the 
efficacy of this method may be confounded by factors such as 
supportive care, antiviral agents, steroids, and intravenous im-
munoglobulin and remains unclear [76].NCLUSION
Currently, there is no FDA approved pharmacologic therapy. 
Disease management is based on prevention and quarantine. 
Pharmacologic therapy choices are all off-label. Several antivi-
ral components are also being administered as off-label therapy. 
Monoclonal Antibodies can also be a treatment choice but are 
restricted by viral mutations and peptide base changes. Vitamins 
B, C, and D appear to be useful in enhancing the immunity sys-
tem of patients with deficiencies. Zinc and Selenium can also 
be used for that purpose. Side effects and contraindications must 
also be taken into account since higher mortality rates are re-
ported in patients with underlying disorders. The use of corti-
costeroids must be limited to specific cases otherwise immunity 
system’s suppression could lead to exacerbation of the disease. 
Depending on SARS-CoV and SARS-CoV-2 high sequence ho-
mology, relevant data can be utilized in choosing therapy. Anti-
virals seem to be the choice of therapy; along with monoclonal 
antibodies. Clinical Trials and more studies need to be conducted 
to determine efficacy and appropriate dosage and therapy period. 
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